CEA-based vaccines

Expert Review of Vaccines

Volumn 1, Issue 1, 2002, Pages 49-63

  Emina, H Huang ^a   Kaufman, Howard L ^a  

^a Columbia University ^*  (United States)

Author keywords

Carcinoembryonic antigen; Clinical trials; Human; Tumor; Vaccine

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; DENDRITIC CELL VACCINE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANTIBODY TITER; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; CANCER; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; CLINICAL TRIAL; CYTOKINE PRODUCTION; EPITOPE MAPPING; GENE EXPRESSION; GENETIC CODE; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR CLONING; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINE PRODUCTION;

ANIMALS; CARCINOEMBRYONIC ANTIGEN; CLONING, MOLECULAR; DENDRITIC CELLS; EPITOPES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; VACCINES; VACCINES, DNA; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 0038176183     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.1.1.49     Document Type: Review

References (92)

1. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colon carcinoma by immunologic tolerance and absorption techniques. J. Exp. Med. 121, 439-486 (1965).
2. Von Kleist S, Burtin P. Localisation cellulaire d'un antigen embryonnaire de tumeurs coliques humains. Int J. Cancer 4, 467-481 (1969).
3. Hodge JW. Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol. Immunother. 43, 127-134 (1996).
4. Beatty JD, Romero C, Brown PW et al. Clinical value of carcinoembryonic antigen. Diagnosis, prognosis and follow-up of patients with cancer. Arch. Surg. 114, 563-567 (1979).
5. Hayes DF. Tumor markers for breast cancer. Hematology/Oncology Clinics of North America 8(3), 485-506 (1994).
6. Vincent RG, Chu TM. Carcinoembryonic antigen in patients with carcinoma of the lung. J. Thorac. Cardiovasc. Surg. 66, 320-328 (1973).
7. Goslin RH, Skarin AT, Zamcheck N. Carcinoembronic antigen: A useful monitor of therapy of small cell lung cancer. JAMA 246, 2173-2176 (1986).
8. Bates SE, Longo DL. Use of serum markers in cancer diagnosis and management. Semin. Surg. Oncol. 14, 102-138 (1987).
9. Cooper MJ, Mackei CR, Skinner DB, Moosa AR. A reappraisal of the value of carcinoembryonic antigen in the management of patients with various neoplasms. Br. J. Surg. 66, 120-123, (1979).
10. Hall RP, Laurence DJ, Carcy D et al. Carcinoembryonic antigen in the urine of patients with urothelial carcinoma. Br. Med. J. 3, 609-611, 1972.
11. Ona SW, Zamcheck N, Blair P et al. CEA in the dianosis of pancreatic cancer. Cancer 31, 324-327 (1973).
12. Shimizu N, Wakatsuki T, Murakami A et al. Carcinoembryonic antigen in gastric cancer patients. Oncology 44, 240-244 (1987).
13. Alexander JC, Chretien PB, Dellon AL, Snyder J. CEA levels in patients with carcinoma of the esophagus. Cancer 42, 1492-1497 (1978).
14. Maxwell P. Carcinoembryonic antigen: cell adhesion molecule and useful diagnostic marker. Br. J. Biomed. Sci. 56, 209-214 (1999).
15. Thompson JA. Molecular cloning and expression of CEA gene family members. Tum. Biol 15, 10-16 (1995).
16. Wanebo JH, Rao G, Pinsky CM, et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N. Engl. J. Med. 299, 448-451 (1978).
17. Bruinvels DJ, Stiggelbout AM, Kievit J, van Houlwelingen HC, Habbema JD, van der Velde CJ. Follow-up of patients with colorectal cancer: A meta-analysis. Ann. Surg. 219, 174-182 (1994).
18. Moertel CG, Fleming TR, Macdonald JS, Haier DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 270(8), 943-947 (1993).
19. Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis. Colon Rectum 37, 272-277 (1994).
20. Huang A, Hindle KS, Tsavellas G. Colorectal surveillance post-surgery. Hosp. Med. 62(8), 490-491 (2001).
21. Martinez DA, Barbera-Guillem E, LaValle GJ, Martin EW. Radioimmunoguided surgery for gastrointestinal malignancies: an analysis of 14 years of clinical experience. Cancer Control 4(6), 505-516 (1997).
22. Tsang KW, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T-cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccina-CEA vaccine. J. Natl. Cancer Inst. 87(13), 982-990 (1995).
23. Tanaka H, Tsunoda T, Nukaya I et al. Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2/neu: possible immunotherapy for colorectal carcinomas. Br. J. Cancer 84(1), 94-99 (2001).
24. Reynolds SR, Celis E, Sette A et al. Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis. J. Immun. Methods 244(1), 59-67 (2000).
25. Bakker AB, Schreurs MW, Tafazzul G et al. Identification of a novel peptide derived from the melanocyte-specific gp 100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted antimelanoma CTL line. Int. J. Cancer 62(1), 97-102 (1995).
26. Pogue RR, Eron J, Frelinger JA, Matsui M. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro imuunogenicity. Proc. Natl Acad. Sci. USA 92(18), 8166-8170 (1995).
27. Lipford GB, Bauer S, Wagner H, Heeg K. Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6. Immunology 84(2), 298-303 (1995).
28. Zaremba S, Barzaga E, Zhu M, Soares N, Tsang K, Schlom J. Identification of an enhancer agonist cytotoxic T-lymphocyte peptide form human carcinoembryonic antigen. Cancer Res. 57, 4570-4577 (1997).
29. Salazar E, Zaremba S, Arlen PM, Tsang KY, Schlom J. Agonist peptide from a cytotoxic T-lymphocyte epitope of human carcinoembryonic antigen stimulates production of Tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide. Int. J. Cancer 85, 829-838 (2000).
30. Fong L, Hou Y, Rivas A et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl Acad. Sci. USA 98(15), 8809-8814 (2001).
31. Shu SY, Rosenberg SA. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res. 45(4), 1657-1662.
32. Elias EG, Suter CM, Fabian DS. Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide. J. Surg. Oncol. 64(1), 17-22 (1997).
33. Du Bois JS, Trehu EG, Mier JW et al. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J. Clin. Oncol. 15(3), 1052-1062 (1997).
34. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocye-macrophage colony-stimulating factor stimulates potent, specific and long-lasting antitumor immunity. Proc. Natl Acad. Sci. USA 90(8), 3539-3543 (1993).
35. Simons JW. Bioactiviry of human GM-CSF gene therapy in metastatic renal cell carcinoma and prostate cancer. Hinyokika Kiyo 43(11), 821-822 (1997).
36. Jaffee EM, Hruban RH, Biedrzycki B et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a Phase I trial of safety and immune activation. J. Clin. Oncol. 19(1), 145-156 (2001).
37. Arlen P, Tsang KY, Marshall JL et al. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunol. Immunother. 49(10), 517-529 (2000).
38. Slingluff CL Jr, Yamshchikov G, Neese P et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer Res. 7(10), 3012-3024 (2001).
39. Pertmer TM, Eisenbraun MD, McCabe D, Prayaga SK, Fuller DH, Haynes JR. Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T-lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 13(15), 1427-1430 (1995).
40. Conry RM, LoBuglio AF, Loechel F et al. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Therapy 2, 59-65 (1995).
41. Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum. Mol. Genet. 1(6), 363-369 (1992).
42. Daro E, Butz E, Smith J, Teepe M, Maliszewski CR, McKenna HJ. Comparison of the functional properties of murine dendritic cells generated in vivo with flt3 ligand, GM-CSF and flt3 ligand plus gm-csf. Cytokine 17(3), 119-130 (2002).
43. Hiasa Y, Akbar SM, Abe M, Michitaka K, Horiike N, Onji M. Dendritic cell subtypes in autoimmune liver diseases; decreased expression of HLA DR and CD 123 on Type 2 dendritic cells. Hepatol Res. 22(4), 241-249 (2002).
44. Lu L, Thomson AW. Manipulation of dendritic cells for tolerance induction in transplantation and autoimmune disease. Transplantation 73(1 Suppl.), S19-22 (2002).
45. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4(3), 269-270 (1998).
46. Rains N, Cannan RJ, Chen W, Stubbs RS. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepato-gastroenterology 48, 347-351 (2001).
47. Kugler A, Stuhler G, Walden P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 6(3), 252-253 (2000).
48. Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl Cancer. Inst. 84(14) (1992).
49. Zhu M, Marshall J, Cole D, Schlom, Tsang KY. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin. Cancer Res. 6, 24-33 (2000).
50. Hammond AL, Plemper RK, Zhang J, Schneider U, Russell SJ, Cattaneo R. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J. Virol. 75(5), 2087-2096 (2001).
51. Xiang R, Silletti S, Lode HN et al. Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice. Clin. Cancer. Res. 7, 856s-864s (2001).
52. Xiang R, Primus FJ, Ruehlmann JM et al. A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T-cell-mediated protective Immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J. Immunol. 167(8), 4560-4565 (2001).
53. Clay TM, Hobeika AC, Mosca PJ, Lyerly HK, Morse MA. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin. Cancer. Res. 7, 1127-1135 (2001).
54. Horig H, Lee DS, Conkright W et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 costimulatory molecule. Cancer Immunol. Immunother. 49, 504-514 (2000)
55. von Mehren M, Arlen P, Gulley J et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. 7(5), 1181-1181 (2001).
56. Hobeika AC, Clay TM, Mosca PJ, Lyerly HK, Morse MA. Quantitating therapeutically relevant T-cell responses to cancer vaccines. Crit. Rev. Immunol. 21 (1-3), 287-297 (2001).
57. Giuletti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 25(4), 386-401 (2001).
58. Freeman WM, Walker SJ, Vrana KE. Quantitative RT-PCR: pitfalls and potential. Biotechniques 26(1), 112-122 (1999).
59. Kim CJ, Reintgen DS, Yeatman TJ. The promise of microarray technology in melanoma care. Cancer Control 9(1), 49-53 (2002).
60. Granucci F, Castagnoli PR, Rogge L, Sinigaglia F. Gene expression profiling in immune cells using microarray. Int. Arch. Allerg. Immunol. 126(4), 257-266 (2001).
61. Armstrong AC, Hawkins RE. Vaccines in oncology: background and clinical potential. Br. J. Radiol 74, 991-1002 (2001).
62. Schwartzentruber DJ. Guidelines for the safe adminstration of high-dose interleukin-2. J. Immunother. 24(4), 287-293 (2001).
63. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4(3), 321-327 (1998).
64. Marshall JL, Hoyer RJ, Toomey MA et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anticarcinoembryonic antigen immune responses. J. Clin. Oncol. 18(23), 3964-3973 (2000).
65. Bronte V, Thung K, Rao JB et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154(10), 5282-5292 (1995).
66. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 70, 83-243 (1998).
67. Robertson MJ, Cameron C, Atkins MB et al. Immunological effects of interleukin-12 administered by bolus iv. injection to patients with cancer. Clin. Cancer Res. 5, 9-16 (1999).
68. Rao JB, Chamberlain RS, Bronte V et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J. Immunol. 156(9), 3357-3365 (1996).
69. Schmitt M, Ikeda H, Nagata Y et al. Involvement of T-cell subsets and natural killer (NK) cells in the growth suppression of murine fibrosarcoma cells transfected with interleukin-12 (IL-12) genes. Int J. Cancer 72(3), 505-511 (1997).
70. Kaufman HL, Flanagan K, Lee CS, Perretta DJ, Horig H. Insertion of interleukin-2 (IL-2) and ilterleukin-12 (IL-12) genes into vaccinia virus results in effective antitumor responses without toxicity. Vaccine 20(13), 1862-1869 (2002).
71. McLaughlin JP, Abrams S, Kantor J et al. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity. J. Immunother. 20(6), 449-459 (1997).
72. Nishisaka N, Maini A, Kinoshita Y et al. Immunotherapy for lung metastases of murine renal cell carcinoma: synergy between radiation and cytokine-producing tumor vaccines. J. Immunother. 22(4), 308-314 (1999).
73. Bretscher P. The two-signal model of lymphocyte activation twenty-one years later. Immunol. Today 13(2), 74-76 (1992).
74. Bluestone JA. New perspectives of CD28-B7-mediated T-cell costimulation. Immunity 2, 555 (1995).
75. Miller SD, Vanderlugt CL, Lenschow DJ et al. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 3, 739 (1995).
76. Yu X, Abe R, Hodes R. The role of B7-CD28 costimulation in tumor rejection. Int Immunology 10, 791 (1998).
77. Eck SC, Turka LA. Generation of protective immunity against an immunogenic carcinoma requires CD40/CD40L and B7/CD28 interactions but not CD4(+) T-cells. Cancer Immunol. Immunother. 48(6), 336-341 (1999).
78. Hodge JW, McLaughlin JP, Abrams SI, Shupert WL, Schlom J, Kantor JA. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res. 55(16), 3598-3603 (1995).
79. von Mehren M, Arlen P, Tsang KY et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res. 6, 2219-2228 (2000).
80. Kwon ED, Foster BA, Hurwitz AA et al. Elimination of residual meatstatic prostate cancer after surgery and adjunctive cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc. Natl Acad Sci. USA 96(26), 15074-15079 (1999).
81. Frauwirth KA, Thompson CB. Activation and inhibition of lymphocytes by costimulation. J. Clin. Invest. 109(3), 295-299 (2002).
82. Shankar P, Schlom J, Hodge JW. Enhanced activation of rhesus T-cells by vectors encoding a triad of costimulatory molecules (B&-1, 1CAM-1, LFA-3). Vaccine 20(5-6), 744-755 (2001).
83. Fujii H, Inobe M, Kimura F et al. Vaccination of tumor cells transfected with the B7-1 (CD80) gene induces the antimetastatic effect and tumor immunity in mice. Int J. Cancer 66(2), 219-224 (1996).
84. Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl Cancer Inst. 89(21), 1595-1601 (1997).
85. Andrew ME, Coupar BE, Boyle DB. Humoral and cell-mediated immune responses to recombinant vaccinia viruses in mice. Immunol. Cell Biol. 67(5), 331-337 (1989).
86. Bruno L, Kirberg J, von Boehmer H. On the cellular basis of immunological T-cell memory. Immunity 2(1), 37-43 (1995).
87. Kundig TM, Bachman MF, Oehen S et al. On the role of antigen in maintaining cytotoxic T-cell memory. Proc. Natl Acad. Sci. USA 93(18), 9716-9723 (1996).
88. Modlin JF, Halsay NA, Thoms ML, Meschievitz CK, Patriarca PA. Humoral and mucosal immunity in infants induced by three sequential inactivated poloiovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. J. Infect. Dis. 175(Suppl. 1), S228-234 (1997).
89. Zannoli R, Morgese G. Hepatitis B vaccine: current issues. Ann. Pharmacother. 31, 1059-1067 (1997).
90. Marshall JL, Hawkins MJ, Tsang KY et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol. 1, 332 (1999).
91. Clarke P, Mann J, Simpson JF, Rickard-Dickson K, Primus FJ. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res. 58(7), 1469-1477, 1998
92. Horig H, Wainstein A, Long L et al. A new mouse model for evaluating the immunotherapy of human colorectal cancer. Cancer Res. 61(23), 8520-8526, 2001.